findmyKOL

Willa Hsueh, MD

Basic profile

The Ohio State University Wexner Medical Center

ORCIDNPI
RegionColumbus, OH · MidwestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Last active 2024findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2024Online presenceNot yet checkedPayments2021 onwardNIH funding2014–2024

Willa Hsueh is an Endocrinology/Metabolic physician affiliated with The Ohio State University Wexner Medical Center. OpenAlex indexes 369 publications with 25,067 citations (h-index 83). By OpenAlex citation count, this profile ranks in the top 5% of Endocrinology, Diabetes & Metabolism profiles in the findmyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
369publications

Distinct works indexed by OpenAlex, matched via ORCID.

25,067citations

Total citations across indexed works.

83h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
9companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
4NIH grants · 2014–2024

Federally funded research awards.

View funding

Industry payments

9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

9 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    71.7%
    GLP-1 receptor agonist28.1%
    Trulicity76%Ozempic24%
    Part D<11 patients
    Insulin Analog19.1%
    Lantus Solostar42%Insulin Lispro Kwikpen U-10026%Tresiba Flextouch U-10017%Basaglar Kwikpen U-10016%
    Part D<11 patients

    + 3 more classes in this area

  • Hormonal (systemic)

    19.9%
    l-Thyroxine17.1%
    Levothyroxine Sodium60%Synthroid40%
    Part D<11 patients
    Thyroid Hormone Synthesis Inhibitor2.8%
    Methimazole100%
    Part D<11 patients
  • Cardiovascular

    4.9%
    Statin4.9%
    Rosuvastatin Calcium100%
    Part D<11 patients
Where care is delivered (Part B)64.2% facility · 35.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

4 NIH research awards on record, funded 20142024 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”